Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Alder Earns $15M Milestone from BMS on the Start of Phase IIa Trial with IL-6-Targeting mAb

BMS-conducted rheumatoid arthritis study will evaluate the safety and efficacy of subcutaneous ALD518/BMS-945429.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »